GYRE THERAPEUTICS, INC. Income Statement
GYRE / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 15 fiscal years. All figures from audited SEC 10-K filings.
GYRE THERAPEUTICS, INC. reported $117M in revenue and $10M in net income for FY2025. Revenue has grown at a 11.6% compound annual rate over the past 14 years.
Based on SEC 10-K filings.
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $116.6M | $105.8M | $102.3M | $102.3M | $7.3M | $20.9M | - | $6.0K | $1.0M | - | - | $87.0K | $3.6M | $57.9M | $25.1M |
| Cost of Revenue | $5.4M | $3.9M | $4.8M | $4.8M | - | - | - | - | - | - | - | - | - | - | $691.0K |
| Gross Profit | - | $101.9M | $97.5M | $97.5M | - | - | - | - | - | - | - | - | - | - | - |
| SG&A Expense | $20.8M | $16.1M | $17.4M | $17.4M | $19.0M | $13.4M | $13.4M | $12.4M | $10.0M | $9.3M | $9.6M | $4.1M | $4.1M | $13.2M | $8.2M |
| R&D Expense | $13.7M | $12.0M | $16.7M | $16.7M | $68.9M | $43.9M | $43.9M | $21.5M | $12.8M | $11.6M | $6.0M | $5.3M | $6.6M | $49.1M | $40.2M |
| Operating Income | $11.5M | $16.2M | $9.2M | $9.2M | -$87.9M | -$57.3M | -$57.3M | -$33.8M | -$21.8M | -$20.4M | -$13.8M | -$7.5M | -$10.1M | -$8.1M | -$40.3M |
| Interest Expense | $1.7M | - | $726.0K | $726.0K | - | - | - | - | - | - | $1.5M | $23.0K | $53.0K | $86.0K | $217.0K |
| Income Tax | $4.6M | $5.3M | $5.1M | $5.1M | - | - | - | - | - | - | - | $3.5M | $7.0K | -$101.0K | -$88.0K |
| Net Income | $9.9M | $17.9M | $4.3M | $4.3M | -$87.9M | -$55.2M | -$55.2M | -$30.1M | -$21.6M | -$16.9M | -$14.8M | -$6.6M | -$10.0M | -$7.0M | -$39.4M |
| EPS (Basic) | $0.06 | -$1.41 | $0.04 | $0.04 | -$2.87 | - | - | - | - | - | - | - | -$0.24 | $0.38 | -$1.54 |
| EPS (Diluted) | $0.02 | -$1.41 | $0.03 | $0.03 | -$2.87 | -$4.60 | -$2.68 | -$2.68 | - | - | - | -$0.21 | -$0.27 | $0.36 | -$1.54 |
| Shares Outstanding | 91.3M | 76.6M | 63.6M | 75.7M | 31.4M | 12.0M | 12.0M | 12.0M | 3.4M | 779.2K | 295.3K | 33.7M | 33.6M | 33.4M | 28.9M |
| Gross Margin | - | 96.3% | 95.3% | 95.3% | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin | 9.8% | 15.3% | 9.0% | 9.0% | -1197.8% | -273.4% | - | -563700.0% | - | - | - | -8631.0% | -278.9% | -14.1% | -160.9% |
| Profit Margin | 8.5% | 16.9% | 4.2% | 4.2% | -1198.3% | -263.4% | - | -500916.7% | - | - | - | -7601.1% | -274.6% | -12.1% | -157.2% |